Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting
MONMOUTH JUNCTION, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company…